Patents by Inventor Bryan L. Betz

Bryan L. Betz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recurrent gene fusions in cutaneous CD30-positive lymphoproliferative disorders
    Patent number: 10590488
    Abstract: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Kojo Elenitoba-Johnson, Mark J. Kiel, Delphine Rolland, Bryan L. Betz, Nathanael G. Bailey, Thirunavukkarasu Velusamy, Megan Lim
  • RECURRENT GENE FUSIONS IN CUTANEOUS CD30-POSITIVE LYMPHOPROLIFERATIVE DISORDERS
    Publication number: 20180010196
    Abstract: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).
    Type: Application
    Filed: January 29, 2016
    Publication date: January 11, 2018
    Inventors: Kojo Elenitoba-Johnson, Mark J. Kiel, Delphine Rolland, Bryan L. Betz, Nathanael G. Bailey, Thirunavukkarasu Velusamy, Megan Lim
  • METHODS AND BIOMARKERS FOR DETECTION AND TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS
    Publication number: 20180010103
    Abstract: The present invention relates to methods and biomarkers for detection and characterization of Langerhans cell histiocytosis in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples). In particular, the present invention provides compositions and methods for diagnosing a patient as having a Langerhans cell histiocytosis by identifying mutations in the MAP2K1 gene or gene products.
    Type: Application
    Filed: January 29, 2016
    Publication date: January 11, 2018
    Inventors: Kojo Elenitoba-Johnson, Mark J. Kiel, Helmut Weigelin, Noah A. Brown, Bryan L. Betz, Megan Lim